Tag: hit
‘Boring is good,’ Teva CEO Schultz says amid push to hit...
Teva’s CEO Kåre Schultz had his hands full when he joined the company back in 2017, and while the drugmaker still faces significant challenges, he's...
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is...
Boehringer Ingelheim and Eli Lilly’s Tradjenta is working to pick up share in an ultracompetitive diabetes market, and it’s hoping some new outcomes data...
